NCT00320229

Half-Dose Intracoronary Abciximab Bolus Improves the Mortality Outcome Compared to Standard Intravenous Regimen

• Status: Terminated
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 84 (planned)
• Sponsor: Azienda Sanitaria Ospedaliera · Academic / Other
• Sex: All
• Age: 50 Years
• Healthy volunteers: Not accepted

Summary

The aim of our study was to demonstrate that, during a percutaneous coronary intervention, even smaller amounts of abciximab than standard dose, injected locally, could achieve a rapid thrombus resolution and clinical improvement without concomitant differences in hemorrhagic complications

Detailed description

Patients both with acute myocardial infarction and unstable angina are prone to extensive intracoronary thrombosis, leading to acute deterioration during percutaneous coronary intervention or thrombosis of the device despite therapy. Intracoronary use of abciximab has reported favourable results. We randomly assigned 84 patients to intracoronary half abciximab bolus (group A) and to standard regimen (group B).

Conditions

• Coronary Disease
• Myocardial Infarction

Interventions

Type	Name	Description
DRUG	abciximab

Timeline

• Start date: 2004-12-01
• Completion: 2005-07-01
• First posted: 2006-05-03
• Last updated: 2006-05-16

Locations

1 site across 1 country: Italy